Kidney cancer, also called renal cancer, is cancer that starts in kidney cells, most commonly renal cell carcinoma. It may invade nearby tissues and spread to distant organs if not detected and treated early.
Super-resolution microscopy showed sunitinib disrupts key cellular structures. Solid-state NMR is revealing atomic-level structures of formulated drugs, supported by a new NSF-funded project.
Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda significantly reduced melanoma recurrence risk in a Phase 3 trial. The FDA has not yet approved the vaccine, with potential availability expected by early 2027.
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
UNM Comprehensive Cancer Center installs MRI-LINAC, enabling real-time tumor tracking and adaptive radiation therapy. The system has treated 10 patients and improves precision, reducing damage to healthy tissue.
Telix gained FDA alignment to advance ProstACT Global Phase 3 into U.S. Part 2 for TLX591-Tx in mCRPC, with safety data from Part 1 deemed sufficient. The trial will combine the therapy with abiraterone, enzalutamide, or docetaxel, pending IND amendment review.
Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.
Novartis expands US radioligand manufacturing with new Texas and North Carolina facilities to bolster domestic production of cancer treatments. Telix Pharmaceuticals reports positive Phase 3 prostate cancer trial data and maintains 2026 revenue guidance of US$950-970 million.
Key oncology developments include a $315 million partnership between Astellas and Vir for the prostate cancer T-cell engager VIR-5500, with updated phase 1 data showing an 82% PSA50 rate. The FDA accepted a filing for Ono Pharmaceuticals' tirabrutinib seeking accelerated approval in primary central nervous system lymphoma. Research findings also identified a new kidney cancer biomarker and showed promising results for the TRK inhibitor repotrectinib and the breast cancer triple therapy gedatolisib plus palbociclib and fulvestrant.
Two JAMA Network Open studies highlight persistent racial disparities in cancer. One found early-onset cancer rates declining in men but rising in women, with significant variation by race across cancer types. A separate analysis of ovarian cancer trials showed Black patients had lower overall survival and were underrepresented in clinical research.
Two innovative CAR-T approaches show promise against solid tumors in preclinical studies. An in vivo gene editing system generates CAR-T cells directly in the body, while HLA-independent T cell receptors target CD70 across various tumor types. Both methods have demonstrated tumor clearance in mouse models, potentially expanding cell therapy applications beyond blood cancers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07672860 |
Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors |
RECRUITING | PHASE2 |
| NCT07646847 |
A Study of a Side Effects and Resource Navigation Program for People With Cancer |
RECRUITING | NA |
| NCT07410676 |
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07401875 |
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) |
RECRUITING | PHASE1 |
| NCT07397611 |
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC |
RECRUITING | PHASE2 |
| NCT07327489 |
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) |
RECRUITING | |
| NCT07297160 |
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07284953 |
A Novel Haemostatic Agent for Robotic Partial Nephrectomy |
WITHDRAWN | NA |
| NCT07243067 |
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer |
NOT_YET_RECRUITING | |
| NCT07123090 |
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma |
RECRUITING | PHASE2 |
